Actively Recruiting
Evaluation of ABO2011 Alone or with Toripalimab for Safety, Pharmacokinetics, and Preliminary Effectiveness in Advanced Solid Tumors
Led by Suzhou Abogen Biosciences Co., Ltd. · Updated on 2026-09-23
218
Participants Needed
5
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ABO2011, alone or combined with Toripalimab, in patients with advanced solid tumors. This open-label, single-group study focuses on assessing safety, tolerability, how the drugs behave in the body, their effects, and early signs of how well they might work. The study includes adults who have progressed after previous treatments or require treatment for selected tumor types. Participants will receive ABO2011 by intratumoral injection either as monotherapy or in combination with Toripalimab. The study has two phases dose escalation and dose expansion. The monotherapy and combination therapy groups are assessed separately, with different timelines for safety monitoring after dosing. The combination therapy safety follow-up lasts longer than monotherapy. Participants receive treatment according to the study plan until criteria for discontinuation are met. During the study, participants undergo evaluations for dose-limiting toxicities, adverse events, serious adverse events, and laboratory test abnormalities for specified periods after dosing depending on the treatment group. Tumor response will be measured up to two years after consent. Safety and pharmacokinetic assessments are conducted throughout treatment and follow-up. The total study duration for each participant varies based on treatment and monitoring schedules.
CONDITIONS
Brief Title
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Research Team
N
Nong Chen
S
Shihui Fu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here